Assembly Biosciences (ASMB) Net Income towards Common Stockholders (2010 - 2026)

Assembly Biosciences' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$11.7 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 17.17% year-over-year to -$11.7 million; the TTM figure through Mar 2026 stood at -$9.0 million (up 78.09% YoY), while the FY2025 annual figure was -$6.1 million, up 84.76% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$11.7 million, down from $22.1 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $22.1 million in Q4 2025, with the low at -$24.7 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is -$11.2 million (2024), against an average of -$12.7 million.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders jumped 313.74% in 2025, then retreated 17.17% in 2026.
• Assembly Biosciences' Net Income towards Common Stockholders stood at -$24.2 million in 2022, then surged by 54.62% to -$11.0 million in 2023, then increased by 5.72% to -$10.3 million in 2024, then soared by 313.74% to $22.1 million in 2025, then sank by 152.95% to -$11.7 million in 2026.
• Business Quant data shows ASMB's Net Income towards Common Stockholders at -$11.7 million in Q1 2026, $22.1 million in Q4 2025, and -$9.2 million in Q3 2025.